Spark Therapeutics (ONCE) Given a $67.00 Price Target at BMO Capital Markets

BMO Capital Markets set a $67.00 price objective on Spark Therapeutics (NASDAQ:ONCE) in a research note published on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also issued reports on ONCE. SunTrust Banks set a $101.00 price objective on Spark Therapeutics and gave the stock a buy rating in a report on Monday, October 16th. Raymond James Financial reissued a buy rating on shares of Spark Therapeutics in a report on Tuesday, December 19th. Royal Bank of Canada decreased their price objective on Spark Therapeutics from $100.00 to $98.00 and set an outperform rating for the company in a report on Wednesday, November 8th. Chardan Capital decreased their price objective on Spark Therapeutics from $100.00 to $60.00 and set a buy rating for the company in a report on Tuesday, December 12th. Finally, Sanford C. Bernstein set a $71.00 price objective on Spark Therapeutics and gave the stock a buy rating in a report on Wednesday, December 13th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $75.86.

Shares of Spark Therapeutics (NASDAQ ONCE) traded up $1.89 during mid-day trading on Tuesday, reaching $53.31. The company had a trading volume of 631,600 shares, compared to its average volume of 539,000. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75. The company has a market cap of $2,050.00 and a price-to-earnings ratio of -7.40.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same period last year, the company earned ($1.07) earnings per share. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. equities research analysts forecast that Spark Therapeutics will post -7.6 earnings per share for the current fiscal year.

In other news, insider Daniel Faga sold 6,000 shares of the firm’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $79.95, for a total transaction of $479,700.00. Following the completion of the sale, the insider now directly owns 6,000 shares of the company’s stock, valued at approximately $479,700. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total value of $356,600.00. Following the sale, the insider now directly owns 215,000 shares of the company’s stock, valued at $15,333,800. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 62,309 shares of company stock valued at $4,621,085. 7.30% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after acquiring an additional 241,016 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Spark Therapeutics by 11.6% during the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after acquiring an additional 213,520 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Spark Therapeutics during the 3rd quarter worth $13,519,000. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Spark Therapeutics during the 3rd quarter worth $5,286,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Spark Therapeutics by 23.8% during the 3rd quarter. Principal Financial Group Inc. now owns 54,088 shares of the biotechnology company’s stock worth $4,822,000 after acquiring an additional 10,399 shares in the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics (ONCE) Given a $67.00 Price Target at BMO Capital Markets” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/01/03/spark-therapeutics-once-given-a-67-00-price-target-at-bmo-capital-markets.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply